ondasdechoque.org
PT-BR

Spasticity after spinal cord injury · Single-group study · 2025

Can shockwave help daily activities with spasticity after a spinal cord injury?

In this small study of 11 people, three sessions of radial shockwave, one a week, were followed by progress on personal everyday goals: 28 of 33 goals improved, and the gains generally lasted through 12 weeks. Movement, pain and walking tests showed no clear overall change.

Personal goals improved over time
adults with spasticity after a spinal cord injury
11
sessions, one a week
3
weeks of follow-up
12

Good to know: Small study (11 people) with no comparison group; some goals had started improving before treatment.

Hellenbrand BSG, van Laake-Geelen CCM, Seelen HAM The Journal of Spinal Cord Medicine, 2025 · Read the paper ↗

How this study worked

StartFollow-up11 people
One group was followed over time, without a comparison group. Each dot is one person.

Conceptual animation: a radial wave spreads from the applicator and weakens with distance. Not to scale. Tap the field to send a pulse.

The treatment

Radial shockwave

Radial, once a week for 3 weeks

Radial wavesSpread out from the skin; strongest near the surface
Sessions
3, one a week
Pulses
2,000 per muscle · at most, for calf muscles; up to 1,000 for wrist and hand muscles
Strength
2.6bar for the calf; 1.5 bar for the wrist and hand, raised step by step within comfort · 15 per second
Numbing
Not mentioned
Device
Storz Masterpuls MP100 Ultra
Everyone also got
Usual therapy could continue; spasticity medicines unchanged

Compared with: No comparison group: each person's results before and after treatment were compared

Settings are what each study used, not a prescription.

Who took part

11 adults (average age about 63) with long-standing incomplete spinal cord injury and spasticity limiting daily life: six treated at the calf, five at the wrist and hand.

Radial shockwave11 people

Side effects

No serious side effects. Five people had brief skin redness; one had tiny red spots and one a slight bruise, both gone within a week. All 11 finished.

All the numbers and the full appraisal

Every reported result

FROM THE FULL PAPER

The results, in numbers.

Eleven adults with chronic SCI (AIS C or D) and function-limiting spasticity: six calf plantar-flexor and five wrist/hand-flexor participants. Table 3 gives mean age 63.36 years (SD 12.19; range 42–80), mean time since injury 9 years (SD 8.1; range 3–29).

Radial ESWT cohort (calf plantar flexors or wrist/hand flexors)11enrolled

Randomized single-case baseline start times; participants were not randomized to ESWT versus control. Six were treated at the calf and five at the wrist/hand. All 11 completed with no missing values.

Goal Attainment Scaling (GAS), individualized ADL item 13 reported outcomes
01
Baseline phase versus 12-week follow-up phase

Goal Attainment Scaling (GAS), individualized ADL item 1

Goal Attainment Scaling (GAS), participant-specific goals GAS points

BaselineFollow-up
Radial ESWT cohort (calf plantar flexors or wrist/hand flexors)
0.53
-22 GAS points
Goal Attainment Scaling (GAS), individualized ADL item 1 · Baseline phase versus 12-week follow-up phase · means
GroupnBaselineFollow-up
Radial ESWT cohort (calf plantar flexors or wrist/hand flexors)10-1.65 (SD 0.76)0.53 (SD 1)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Among the 10 participants with a statistically significant higher score for this ranked personal goal, the follow-up mean was higher than the baseline mean. Personalized ordinal goals and the lack of a control arm limit interpretation; this is not an estimate of comparative treatment effect.

Analysis details and source

Reported means are for the 10 participants identified as having significantly higher scores for this individualized goal; they are not a randomized between-arm comparison. Item 1: baseline vs follow-up phase, P <0.01.

02
Baseline phase versus 12-week follow-up phase

Goal Attainment Scaling (GAS), individualized ADL item 2

Goal Attainment Scaling (GAS), participant-specific goals GAS points

BaselineFollow-up
Radial ESWT cohort (calf plantar flexors or wrist/hand flexors)
0
-22 GAS points
Goal Attainment Scaling (GAS), individualized ADL item 2 · Baseline phase versus 12-week follow-up phase · means
GroupnBaselineFollow-up
Radial ESWT cohort (calf plantar flexors or wrist/hand flexors)10-1.47 (SD 0.81)0 (SD 1.05)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Among the 10 participants with a statistically significant higher score for this ranked personal goal, the follow-up mean was higher than the baseline mean. Personalized ordinal goals and the lack of a control arm limit interpretation; this is not an estimate of comparative treatment effect.

Analysis details and source

Reported means are for the 10 participants identified as having significantly higher scores for this individualized goal; they are not a randomized between-arm comparison. Item 2: baseline vs follow-up phase, P ≤0.01.

03
Baseline phase versus 12-week follow-up phase

Goal Attainment Scaling (GAS), individualized ADL item 3

Goal Attainment Scaling (GAS), participant-specific goals GAS points

BaselineFollow-up
Radial ESWT cohort (calf plantar flexors or wrist/hand flexors)
-0.11
-22 GAS points
Goal Attainment Scaling (GAS), individualized ADL item 3 · Baseline phase versus 12-week follow-up phase · means
GroupnBaselineFollow-up
Radial ESWT cohort (calf plantar flexors or wrist/hand flexors)8-1.94-0.11 (SD 0.74)

Values are group summaries identified in the caption; SD denotes standard deviation. CI is a confidence interval; IQR denotes the reported quartiles. A dash means no value was extracted for that cell.

Among the 8 participants with a statistically significant higher score for this ranked personal goal, the follow-up mean was higher than the baseline mean. Personalized ordinal goals and the lack of a control arm limit interpretation; this is not an estimate of comparative treatment effect.

Analysis details and source

Reported means are for the 8 participants identified as having significantly higher scores for this individualized goal; they are not a randomized between-arm comparison. Item 3: baseline vs follow-up phase, P <0.01. The source gives 0.24 after the baseline mean but does not label that parenthetical as SD; it is not coded as SD.

Number of individualized GAS items reported as improved after ESWT1 reported outcome
04
After three-week treatment and during 12-week follow-up

Number of individualized GAS items reported as improved after ESWT

Goal Attainment Scaling (GAS) items

The authors state descriptively that 28 of 33 individualized GAS items improved after ESWT and that improvement was generally maintained during follow-up. Goal items are repeated within 11 participants and are not 33 independent people.

Analysis details and source

Abstract and Discussion report 28/33 improved; the article does not provide a control comparison or inferential estimate for this pooled item count.

Active and passive range of motion (AROM/PROM)1 reported outcome
05
Baseline and follow-up phases

Active and passive range of motion (AROM/PROM)

Goniometer AROM/PROM varies by measure

The article reports large individual variability and no convincing distinct improvement or deterioration between baseline and follow-up for secondary measures. Numeric results were directed to a supplementary file that was not available in the acquired source.

Analysis details and source

No numeric estimate is extracted because the article body does not provide the supplementary outcome values. It is not interpreted as proof of no effect.

Pain in the treatment region1 reported outcome
06
Baseline and follow-up phases

Pain in the treatment region

Visual Analogue Scale (VAS), 0–10 cm varies by measure

The article reports large individual variability and no convincing distinct improvement or deterioration between baseline and follow-up for secondary measures. Numeric results were directed to a supplementary file that was not available in the acquired source.

Analysis details and source

No numeric estimate is extracted because the article body does not provide the supplementary outcome values. It is not interpreted as proof of no effect.

Walking speed/function1 reported outcome
07
Baseline and follow-up phases

Walking speed/function

10-m walking test (10MWT), calf-treatment subgroup varies by measure

The article reports large individual variability and no convincing distinct improvement or deterioration between baseline and follow-up for secondary measures. Numeric results were directed to a supplementary file that was not available in the acquired source.

Analysis details and source

No numeric estimate is extracted because the article body does not provide the supplementary outcome values. It is not interpreted as proof of no effect.

Arm/hand function1 reported outcome
08
Baseline and follow-up phases

Arm/hand function

Van Lieshout arm–hand test for Tetraplegia, short form (VLT-sf), hand-treatment subgroup varies by measure

The article reports large individual variability and no convincing distinct improvement or deterioration between baseline and follow-up for secondary measures. Numeric results were directed to a supplementary file that was not available in the acquired source.

Analysis details and source

No numeric estimate is extracted because the article body does not provide the supplementary outcome values. It is not interpreted as proof of no effect.

How treatment was delivered
Device and treatment head

Storz Masterpuls MP100 Ultra with D-Actor head.

Modality and target

Radial ESWT over the skin above ankle plantar-flexor muscles or wrist/hand flexors; one side and one extremity per participant.

Calf settings

Maximum 2,000 shocks per muscle belly, 2.6 bar, 15 Hz.

Hand/wrist settings

Maximum 1,000 shocks per muscle belly, 1.5 bar, 15 Hz.

Schedule and titration

Three weekly sessions with six-day intervals; intensity increased until no notable further reduction in tone, stopping at participant pain tolerance or when the therapist felt muscle relaxation. Average device treatment time was 10 minutes.

Co-interventions and comparator

No physical therapy was part of the ESWT intervention; usual therapy could continue and oral antispastic medication was unchanged. No sham/control group.

HARMS & TOLERABILITY

No serious adverse events or symptoms were reported. Five participants had transient redness; one had petechiae and one a slight bruise at the treatment site, with both latter findings resolved by one week. All 11 completed.

LIMITS OF THE ANALYSIS

Unblinded single-case design with no concurrent comparator; the therapist also performed the measurements.

Several participants began improving before ESWT and GAS goals are individualized ordinal outcomes; causality is uncertain.

Secondary outcome numeric results are in cited supplementary material that was unavailable in the acquired source.

Small single-center sample; participants with important comorbidities were excluded, limiting generalizability.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Unblinded single-case design with no concurrent comparator; the therapist also performed the measurements.
  • Several participants began improving before ESWT and GAS goals are individualized ordinal outcomes; causality is uncertain.
  • Secondary outcome numeric results are in cited supplementary material that was unavailable in the acquired source.
  • Small single-center sample; participants with important comorbidities were excluded, limiting generalizability.
Research review

Source-linked critical reading

Multiple single-case experiments with randomized baseline length

Reading depthMaterial consulted
Technical source record

Complete full-article HTML read, including all article sections, three tables and both figure captions. The source links Supplementary_file.docx, which could not be retrieved; secondary numerical outcomes remain unavailable.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Design

A replicated multiple single-case experimental design used randomized baseline lengths (4–8 measurements), followed by three weekly treatment sessions and 12 weeks of follow-up. This is not a parallel-group randomized trial: randomization concerned the intervention start point for each case.

Participants

Eleven adults with chronic SCI and spastic paresis were enrolled: six received treatment to calf plantar flexors and five to wrist/hand flexors. Table 3 reports mean age 63.36 (SD 12.19; range 42–80), mean time since injury 9 years (SD 8.1; range 3–29), and mostly men; participants had AIS C or D and no MAS grade 3–4. All 11 completed without missing values.

Intervention

Radial ESWT was applied once weekly for three weeks at six-day intervals, with no physical therapy delivered as part of the intervention; usual therapies could continue and oral antispastic medication remained unchanged. Device: Storz Masterpuls MP100 Ultra with D-Actor head. Calf: maximum 2,000 shocks per muscle belly, 2.6 bar, 15 Hz. Hand: maximum 1,000 shocks per muscle belly, 1.5 bar, 15 Hz. Intensity was titrated to muscle relaxation and participant pain tolerance.

Comparator

There was no sham or untreated comparison arm. Randomized baseline timing was intended to help link changes with intervention onset, but it does not replace a concurrent control and several participants improved before ESWT began.

Outcomes and follow-up

The primary outcome was GAS: each person set three ranked, individualized activity goals scored from −2 (baseline) to +2 (much better than the target). Secondary outcomes were ankle/wrist-hand AROM/PROM, treatment-region pain VAS, 10-m walking test for calf participants, and VLT-sf for wrist/hand participants. Secondary numerical results were placed in a cited supplementary file that was unavailable; follow-up extended 12 weeks.

Within-person findings

The authors report improvement in 28/33 personal GAS items, generally maintained through follow-up. For item 1, 10 participants had a significant phase increase (baseline mean −1.65, SD 0.76; follow-up 0.53, SD 1.00; P<0.01); item 2: 10 participants (−1.47, SD 0.81 to 0.00, SD 1.05; P≤0.01); item 3: eight participants (−1.94 to −0.11, follow-up SD 0.74; P<0.01). These within-case/phase results are not a controlled estimate. The source reports that GAS improvement began before treatment in four participants for item 1, six for item 2 and two for item 3. Secondary measures showed no convincing distinct phase differences.

Harms and tolerability

No serious adverse events or symptoms were reported. Five participants had brief skin redness, one had petechiae and one a slight bruise at the treatment site; petechiae and bruising had resolved a week later. The article reports all 11 completed.

Limitations and uncertainty

The study was unblinded; the treating therapist also performed assessments, creating measurement and expectation risks. GAS goals were personalized, ordinal, and partly rated by telephone. Participants sometimes improved before treatment, day-to-day performance fluctuated, and several activity goals were not achieved. The cohort was small, from one rehabilitation center, mostly men with incomplete SCI, and excluded common comorbidities. Spasticity was not measured after treatment, so the mechanism linking tone change to activity was not quantified. Secondary outcomes are not numerically reviewable without the unavailable supplement.

Applicability

This exploratory result applies to selected adults in the chronic phase after SCI, with incomplete injury and mild-to-moderate spasticity, treated at one center. It suggests that some individually chosen activities may improve, but cannot show that ESWT caused those changes or establish a dose for other body regions or patients.

What stronger research should do

A larger preregistered randomized trial should include a credible comparator, blinded outcome assessors, repeated spasticity and activity measurements, standardized GAS scoring, prespecified handling of early trends and multiplicity, complete numerical secondary outcomes, and longer systematic harm monitoring. It should include broader injury patterns and report body-region-specific doses.

THE ORIGINAL SOURCE

Read the original article.

Shockwave therapy in persons with a spinal cord injury and spasticity: A multiple single-case experimental design study.

Hellenbrand BSG, van Laake-Geelen CCM, Seelen HAM. · The journal of spinal cord medicine · 2025

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →